Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

28. September 2004 12:59 ET | Quelle: Gardant Pharmaceuticals, Inc.

Bioaccelerate Portfolio Company Inncardio Inc. Enters into Licence and Co-development Agreement for INC 105 with the University of Strathclyde

NEW YORK, Sept. 28, 2004 (PRIMEZONE) -- Bioaccelerate Holdings, Inc. (OTCBB:BACL) a pharmaceutical development organization today announced that one of its portfolio companies, Inncardio Inc., a...
28. September 2004 12:01 ET | Quelle: Gardant Pharmaceuticals, Inc.

Bioaccelerate Portfolio Company Inncardio Inc. Enters into Licence and Co-development Agreement for INC 105 with the University of Strathclyde

NEW YORK, Sept. 28, 2004 (PRIMEZONE) -- Bioaccelerate Holdings, Inc. (OTCBB:BACL) a pharmaceutical development organization today announced that one of its portfolio companies, Inncardio Inc., a...
12. August 2004 12:16 ET | Quelle: Gardant Pharmaceuticals, Inc.

UPDATE: Bioaccelerate Portfolio Company Enhance Biotech to Merge with Privately-Held Ardent Pharmaceuticals -- the World Leader in the Discovery and Development of Delta Receptor Compounds

NEW YORK, Aug. 12, 2004 (PRIMEZONE) -- Bioaccelerate, Inc. , a pharmaceutical development organisation has today announced that one of its portfolio companies, Enhance Biotech Inc (Pink Sheets:EBOI),...
12. August 2004 10:53 ET | Quelle: Gardant Pharmaceuticals, Inc.

Bioaccelerate Portfolio Company Enhance Biotech to Merge with Privately-Held Ardent Pharmaceuticals -- the World Leader in the Discovery and Development of Delta Receptor Compounds

NEW YORK, Aug. 12, 2004 (PRIMEZONE) -- Bioaccelerate, Inc. , a pharmaceutical development organisation has today announced that one of its portfolio companies, Enhance Biotech Inc (Pink Sheets:EBOI),...

Vorherige Seite